Reviva Pharmaceuticals (NASDAQ:RVPH) Shares Down 8.5%

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) were down 8.5% during mid-day trading on Thursday . The company traded as low as $1.02 and last traded at $1.07. Approximately 382,151 shares traded hands during trading, an increase of 27% from the average daily volume of 300,759 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on RVPH shares. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Reviva Pharmaceuticals in a research note on Thursday, July 11th. Benchmark reiterated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, May 28th.

Reviva Pharmaceuticals Stock Performance

The business has a 50 day moving average price of $1.27 and a two-hundred day moving average price of $2.65. The stock has a market cap of $28.20 million, a PE ratio of -0.64 and a beta of -0.09.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Tuesday, May 14th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. As a group, research analysts anticipate that Reviva Pharmaceuticals Holdings, Inc. will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new stake in Reviva Pharmaceuticals during the 4th quarter valued at $72,000. Vanguard Group Inc. grew its position in shares of Reviva Pharmaceuticals by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 1,001,836 shares of the company’s stock valued at $3,787,000 after purchasing an additional 26,854 shares in the last quarter. Finally, Armistice Capital LLC grew its position in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.